{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-039520","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2025-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.829566+00:00","generated_at":"2026-05-24T18:43:54.390354+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Acrivon appoints Adam Levy as CFO; Rasmus Holm-Jorgensen steps down effective April 1, 2025","bullets":["Rasmus Holm-Jorgensen resigns as CFO effective April 1, 2025, for personal reasons to pursue Europe-based opportunity; no disagreement.","Adam Levy, current SVP Corporate Affairs & Investor Relations, appointed CFO effective April 1, 2025.","Levy's annual base salary set at $490,000, bonus target 40%, plus 35,209 stock options vesting over 4 years.","Levy has over 25 years biopharma finance/IR experience, previously at Gilead, Turning Point Therapeutics, Zentalis.","Levy required to relocate to Boston area within 9 months; up to $50,000 relocation reimbursement with 24-month clawback."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-039520","json":"https://secwatch.observer/filing/0000950170-25-039520.json","markdown":"https://secwatch.observer/filing/0000950170-25-039520.md","text":"https://secwatch.observer/filing/0000950170-25-039520.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025039520/0000950170-25-039520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025039520/acrv-20250311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T18:43:54.390354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"179e9538da","claim":"Rasmus Holm-Jorgensen resigned as Chief Financial Officer at Acrivon Therapeutics, Inc..","evidence_excerpt":"On March 11, 2025, Rasmus Holm-Jorgensen, the Company’s Chief Financial Officer, notified the Company of his decision to step down from his position, effective April 1, 2025, for personal reasons to pursue another opportunity with a company based in Europe, allowing him to spend more time near his family.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025039520/0000950170-25-039520-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"e0752469ed","claim":"Adam Levy was appointed as Chief Financial Officer at Acrivon Therapeutics, Inc..","evidence_excerpt":"On March 14, 2025, Acrivon Therapeutics, Inc. (the “Company”) appointed Adam Levy, Ph.D., M.B.A., to the position of Chief Financial Officer, effective as of April 1, 2025 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781174/000095017025039520/0000950170-25-039520-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}